Clinical study of entecavir on treating hepatitis B related hepatic carcinoma after radical operation

doi:10.3969/j.issn.1674-3806.2016.02.14

Abstract：Objective To explore the effects of entecavir on the antiviral treatment for HBV-DNA positive primary hepatocellular carcinoma( HCC) .Methods 60 patients with HBV-DNA positive HCC after radical operation were randomly divided into the observation group(n=35) and the control group(n=25).Both of the two groups re-ceived the conventional anti-inflammatory therapy and liver-protecting treatment.Besides, entecavir was given to the observation group as an anti-HBV therapy 0.5 mg per day for more than 48 weeks 1 to 2 weeks after the radical opera-tion.The liver function, HBV-DNA ration, AFP and disease-free survival rate of the patients were compared between the two groups.Results ( 1 ) HBV-DNA loads and AFP level declined in the observation group significantly than those did in the control group after 3 and 6 months′treatment(P<0.01);(2)The levels of ALT, AST, ALP, GGT in the observation group declined after 1 and 6 month′s treatment.There were no significant changes of the levels of ALT, AST, ALP, GGT in the control groups after 1 month′s treatment.On the contrary, the levels of the above indi-cators increased after 6 months′treatment in the control groups.There were significant differences on the levels of the indicators between the two groups(P<0.01);(3)Followed up for 3 years, 19 cases died, in which 13 cases were in the control group and 6 cases in the observation group, with a significantl difference in disease-free survival rate be-tween the two groups( P<0.01) .Conclusion Entecavir Antiviral treatment with entecavir can reduce the viral load, improve liver function after radical operation, reduce the recurrence rate and prolong the survival time.